CNTG News and Press, Centogene N.V. From 03/09/23

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the appointment of Ian Rentsch as Chief Commercial Officer and Gen...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 08, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for March 2023. CENTOGENE representatives ...

FTD is a rare and rapidly progressing neurodegenerative disease caused by multiple hereditary factors, including mutations in the progranulin ( GRN ) gene The observational EFRONT study is increasing the number of sites to expand access to geographic specific clinicians actively engaged i...

Nasdaq has notified the life sciences company, Centogene ( NASDAQ: CNTG ), that it has regained compliance with the stock exchange's minimum bid price requirement. The stock exchange said Centogene is now compliant with all applicable Nasdaq listing standards, and the matter is n...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has received a notification from the Nasdaq Stock Mark...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its partnering conference schedule for February 2023, with a focus ...

Twist Bioscience ( NASDAQ: TWST ) and Centogene ( NASDAQ: CNTG ) said they launched three next-generation sequencing (NGS) target enrichment panels to support rare disease and hereditary cancer research and diagnostics. Target enrichment panels enable in-depth sequencing o...

Combining expertise to advance precision medicine, while enabling efficient and timely insights into the diagnosis of rare diseases and hereditary cancer around the world Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offerin...

The Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of disease progression, diagnosis, and treatment for patients Having recently reached a significant milestone of testing over 12,500 participants, the study ...

Premier Research and CENTOGENE Launch Strategic Partnership to Accelerate and De-Risk Rare Disease Clinical Development PR Newswire Leveraging Rare Disease Insights Powered by the CENTOGENE Biodatabank and Centralized Multiomic Laboratories in Clinical Trials MOR...